Address correspondence to Dr Peggy M. A. Richter, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Suite FG47, Toronto, ON M4N 3M5, Canada, Peggy.Richter@sunnybrook.ca.
RELATIONSHIP DISCLOSURE: Dr Richter serves on the editorial board of the Journal of Obsessive-Compulsive and Related Disorders, has received personal compensation for speaking engagements from Lundbeck, and receives grant/research support from the Canadian Institutes of Health Research. Dr Ramos reports no disclosure.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Drs Richter and Ramos discuss the unlabeled/investigational use of neuromodulation technology (deep brain stimulation, electroconvulsive therapy, and repetitive transcranial magnetic stimulation) and pharmacologic agents (citalopram, escitalopram, desvenlafaxine, duloxetine, mirtazapine, and venlafaxine) for the treatment of obsessive-compulsive disorder (some of which are approved for use in depression and psychosis).
CONTINUUM AUDIO INTERVIEW AVAILABLE ONLINE